ANAB - ANAPTYSBIO INC
Form 424B4 Period: JAN.26.17 Date Filed: JAN.26.17
Transcript Split
  
  
     
Move to First Section Move to Last Section
INDEX
Page-by-Page
  Form 424B4 (Entire Filing)

Filing Body

Page 1: Filed Pursuant to Rule 424(b)(4)

Page 2: TABLE OF CONTENTS

Page 3: PROSPECTUS SUMMARY

Page 4: in vivo

Page 5: N/A

Page 6: The Advantages of Our SHM Platform

Page 7: Our Collaborations

Page 8: Milestones

Page 9: Our Strategy

Page 10: Financial Update

Page 11: Corporate Information

Page 12: Implications of Being an Emerging Growth Company

Page 13: THE OFFERING

Page 14: N/A

Page 15: SUMMARY CONSOLIDATED FINANCIAL DATA

Page 16: N/A

Page 17: RISK FACTORS

Page 18: We have recently initiated dosing of ANB020 in humans and have never dosed any of our other wholly-o

Page 19: We and/or our collaborators may be unable to obtain, or may be delayed in obtaining, required regula

Page 20: N/A

Page 21: We may not be successful in our efforts to use and expand our technology platform to build a pipelin

Page 22: We face significant competition, and if our competitors develop and market products that are more ef

Page 23: N/A

Page 24: Our product candidates may not achieve adequate market acceptance among physicians, patients, health

Page 25: If companion diagnostics for our product candidates for which such diagnostics are required, are not

Page 26: Risks Related to Our Financial Position and Capital Needs

Page 27: We will require additional capital to finance our operations, which may not be available to us on ac

Page 28: N/A

Page 29: Raising additional capital may cause dilution to our existing stockholders, restrict our operations

Page 30: We currently have no marketing and sales force. If we are unable to establish effective sales or mar

Page 31: The manufacture of biotechnology products is complex and manufacturers often encounter difficulties

Page 32: Our operations are vulnerable to interruption by fire, earthquake, power loss, telecommunications fa

Page 33: We may not succeed in establishing and maintaining additional development collaborations, which coul

Page 34: Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters

Page 35: Our failure to obtain regulatory approval in international jurisdictions would prevent us from marke

Page 36: We plan to seek Orphan Drug Designation for ANB019 or certain of our other product candidates and we

Page 37: Any drugs we develop may become subject to unfavorable third-party reimbursement practices and prici

Page 38: Recently enacted legislation may increase the difficulty and cost for us to obtain marketing approva

Page 39: We may face difficulties from changes to current regulations and future legislation.

Page 40: Our business entails a significant risk of product liability and our ability to obtain sufficient in

Page 41: Our relationships with customers and third-party payors will be subject to applicable anti-kickback,

Page 42: Our employees may engage in misconduct or other improper activities, including noncompliance with re

Page 43: N/A

Page 44: We may not be able to protect our intellectual property rights throughout the world.

Page 45: Obtaining and maintaining our patent protection depends on compliance with various procedural, docum

Page 46: Our reliance on third parties requires us to share our trade secrets, which increases the possibilit

Page 47: If we breach the license agreements related to our product candidates, we could lose the ability to

Page 48: Third parties may initiate legal proceedings against us alleging that we infringe their intellectual

Page 49: We may be subject to claims by third parties asserting that our employees or we have misappropriated

Page 50: Risks Related to this Offering and Ownership of Our Common Stock

Page 51: We will have broad discretion in the use of the net proceeds from this offering and may not use them

Page 52: If you purchase our common stock in this offering, you will incur immediate and substantial dilution

Page 53: We will incur increased costs as a result of operating as a public company, and our management will

Page 54: Sales of a substantial number of shares of our common stock in the public market could cause our sto

Page 55: We do not intend to pay dividends on our common stock so any returns will be limited to the value of

Page 56: We plan to use potential future operating losses and our federal and state net operating loss, or NO

Page 57: SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

Page 58: MARKET AND INDUSTRY DATA

Page 59: USE OF PROCEEDS

Page 60: DIVIDEND POLICY

Page 61: CAPITALIZATION

Page 62: N/A

Page 63: DILUTION

Page 64: N/A

Page 65: SELECTED CONSOLIDATED FINANCIAL DATA

Page 66: N/A

Page 67: MANAGEMENT S DISCUSSION AND ANALYSIS OF

Page 68: in vivo

Page 69: in vivo

Page 70: Research and Development

Page 71: Change in Fair Value of Liability for Preferred Stock Warrants

Page 72: Revenue Recognition

Page 73: Research and Development Expenses

Page 74: Common Stock Valuations

Page 75: Methods Used to Allocate Our Enterprise Value to Classes of Securities

Page 76: Accounting Pronouncements Recently Adopted

Page 77: The JOBS Act

Page 78: in vivo

Page 79: General and Administrative

Page 80: Comparison of the Years Ended December 31, 2014 and 2015

Page 81: General and Administrative

Page 82: Research and Development

Page 83: Funding Requirements

Page 84: Investing Activities

Page 85: Off-Balance Sheet Arrangements

Page 86: BUSINESS

Page 87: Our Product Candidates

Page 88: The Advantages of Our SHM Platform

Page 89: Our Strategy

Page 90: N/A

Page 91: Milestones

Page 92: N/A

Page 93: Our Collaborations

Page 94: Figure 1. Types of cells and cytokines modulated by IL-33. When triggered by pathogens, toxins, viru

Page 95: Figure 2. IL-33 intracellular signaling. IL-33 binds to ST2 that is expressed on the cell surface an

Page 96: in vitro

Page 97: Clinical Development Plan

Page 98: Figure 5. Anticipated ANB020 clinical development strategy.

Page 99: Peanut Allergy.

Page 100: ANB019: Anti-IL-36R Antibody

Page 101: ANB019 Description

Page 102: Clinical Development Plan

Page 103: Figure 8. Anticipated ANB019 clinical development strategy.

Page 104: ANB019 Market Opportunity

Page 105: Our SHM Antibody Discovery Platform

Page 106: Limitations of Competing Antibody Technologies

Page 107: Human B cell screening methodologies

Page 108: in vivo

Page 109: Collaborations

Page 110: Celgene

Page 111: License Agreement with Millipore

Page 112: ANB020

Page 113: Manufacturing

Page 114: Competition

Page 115: Government Regulation and Product Approval

Page 116: N/A

Page 117: Foreign clinical studies to support an IND

Page 118: Orphan drug designation

Page 119: Additional controls for biologics

Page 120: Post-approval requirements

Page 121: Other U.S. healthcare laws and compliance requirements

Page 122: N/A

Page 123: Coverage, pricing and reimbursement

Page 124: Healthcare reform

Page 125: The Foreign Corrupt Practices Act

Page 126: Europe / rest of world government regulation

Page 127: N/A

Page 128: Other regulations

Page 129: MANAGEMENT

Page 130: Matthew Moyle, Ph.D.

Page 131: Nicholas B. Lydon, Ph.D., FRS

Page 132: John P. Schmid, M.B.A.

Page 133: Board Composition

Page 134: Committees of the Board of Directors

Page 135: Compensation Committee

Page 136: Non-Employee Director Compensation

Page 137: EXECUTIVE COMPENSATION

Page 138: Employment Agreements

Page 139: Outstanding Equity Awards at Fiscal Year-End Table

Page 140: Potential Payments upon IPO, Termination or Change in Control

Page 141: Change in Control

Page 142: 2017 Equity Incentive Plan

Page 143: N/A

Page 144: N/A

Page 145: 2017 Employee Stock Purchase Plan

Page 146: 401(k) Plan

Page 147: N/A

Page 148: CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

Page 149: Participation in this Offering

Page 150: Policies and Procedures for Related Party Transactions

Page 151: PRINCIPAL STOCKHOLDERS

Page 152: N/A

Page 153: N/A

Page 154: DESCRIPTION OF CAPITAL STOCK

Page 155: Warrants

Page 156: Form S-3 Registration Rights

Page 157: Delaware Law

Page 158: Transfer Agent and Registrar

Page 159: SHARES ELIGIBLE FOR FUTURE SALE

Page 160: Rule 701

Page 161: MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS

Page 162: Non-U.S. Holder Defined

Page 163: Sale of Common Stock

Page 164: Backup Withholding and Information Reporting

Page 165: Foreign Account Tax Compliance Act

Page 166: UNDERWRITING

Page 167: N/A

Page 168: N/A

Page 169: Offer Restrictions Outside the United States

Page 170: Notice to prospective investors in the United Kingdom

Page 171: Notice to prospective investors in Canada

Page 172: Notice to prospective investors in Switzerland

Page 173: Notice to prospective investors in Japan

Page 174: Notice to prospective investors in Singapore

Page 175: Notice to prospective investors in the British Virgin Islands

Page 176: Notice to prospective investors in Taiwan

Page 177: LEGAL MATTERS

Page 178: INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

Page 179: REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Page 180: ANAPTYSBIO, INC.

Page 181: ANAPTYSBIO, INC.

Page 182: ANAPTYSBIO, INC.

Page 183: ANAPTYSBIO, INC.

Page 184: ANAPTYSBIO, INC.

Page 185: Property and Equipment

Page 186: Milestone Revenue.

Page 187: Warrants for Shares of Preferred Stock

Page 188: Functional Currency of Foreign Operations

Page 189: Recent Accounting Pronouncements

Page 190: Financial Instruments Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and

Page 191: in vivo

Page 192: Other Collaborative Agreements

Page 193: Convertible Promissory Notes Payable to Related Parties

Page 194: Marketable Securities.

Page 195: Fair Value of Other Financial Instruments

Page 196: Dividend Rights.

Page 197: Common Shares

Page 198: Stock Options

Page 199: 9. Employee Benefit Plan

Page 200: Letter of Credit

Page 201: N/A

Page 202: 12. Subsequent Event

Page 203: ANAPTYSBIO, INC.

Page 204: ANAPTYSBIO, INC.

Page 205: ANAPTYSBIO, INC.

Page 206: ANAPTYSBIO, INC.

Page 207: Cash and Cash Equivalents

Page 208: Milestone Revenue.

Page 209: Functional Currency of Foreign Operations

Page 210: Accounting Pronouncements Recently Adopted

Page 211: Financial Instruments Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and

Page 212: Accrued Expenses

Page 213: in vivo

Page 214: N/A

Page 215: 6. Fair Value Measurements

Page 216: Fair Value of Other Financial Instruments

Page 217: Stock Options

Page 218: 9. Australia Research and Development Tax Incentive

Page 219: 5,000,000 Shares

   CURRENT PAGE
    Download Current Page as a Word Document  Download Current Page as a PDF Document    Download Excel File of Financials